EA201691079A1 - Комбинированная терапия для лечения онкологического заболевания - Google Patents

Комбинированная терапия для лечения онкологического заболевания

Info

Publication number
EA201691079A1
EA201691079A1 EA201691079A EA201691079A EA201691079A1 EA 201691079 A1 EA201691079 A1 EA 201691079A1 EA 201691079 A EA201691079 A EA 201691079A EA 201691079 A EA201691079 A EA 201691079A EA 201691079 A1 EA201691079 A1 EA 201691079A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
combined therapy
oncological disease
oncological
disease
Prior art date
Application number
EA201691079A
Other languages
English (en)
Russian (ru)
Inventor
Хайке КАЙЛЬХАК
Сара К. Кнутсон
Кевин У. КУНЦ
Original Assignee
Эпизим, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизим, Инк. filed Critical Эпизим, Инк.
Publication of EA201691079A1 publication Critical patent/EA201691079A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201691079A 2013-12-06 2014-12-08 Комбинированная терапия для лечения онкологического заболевания EA201691079A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361913063P 2013-12-06 2013-12-06
US201461934388P 2014-01-31 2014-01-31
US201461992881P 2014-05-13 2014-05-13
PCT/US2014/069167 WO2015085325A1 (en) 2013-12-06 2014-12-08 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
EA201691079A1 true EA201691079A1 (ru) 2017-03-31

Family

ID=53274220

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691079A EA201691079A1 (ru) 2013-12-06 2014-12-08 Комбинированная терапия для лечения онкологического заболевания

Country Status (13)

Country Link
US (4) US20160303135A1 (enExample)
EP (2) EP3888659A1 (enExample)
JP (4) JP2016539134A (enExample)
KR (3) KR20210117347A (enExample)
CN (2) CN116019921A (enExample)
AU (2) AU2014360078A1 (enExample)
BR (1) BR112016012713A2 (enExample)
CA (1) CA2931263A1 (enExample)
EA (1) EA201691079A1 (enExample)
ES (1) ES2863996T3 (enExample)
IL (3) IL282741B2 (enExample)
MX (1) MX373187B (enExample)
WO (1) WO2015085325A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
IL308807B2 (en) 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
CN110898067A (zh) 2012-10-15 2020-03-24 Epizyme股份有限公司 癌症治疗方法
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
PL3157527T3 (pl) 2014-06-17 2023-08-07 Epizyme, Inc. Inhibitory ezh2 do leczenia chłoniaka
CN106794177A (zh) 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
BR112017010166A2 (en) 2014-11-17 2018-02-14 Epizyme, Inc. solid tumor treatment method, activity inhibition method, oral dosage form for treating a solid tumor, solid pharmaceutical formulation, process for preparing a pharmaceutical formulation, and solid pharmaceutical composition
CN108135908A (zh) 2015-04-20 2018-06-08 Epizyme股份有限公司 用于治疗癌症的组合疗法
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
WO2017019721A2 (en) * 2015-07-28 2017-02-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
SG10201909413SA (en) * 2015-10-06 2019-11-28 Epizyme Inc Method of treating medulloblastoma with an ezh2 inhibitor
EP3386513A2 (en) * 2015-12-07 2018-10-17 Epizyme Inc Inhibitors of ezh2 and methods of use thereof
CA3011186A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
EA201892075A1 (ru) * 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
JP7121660B2 (ja) 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
WO2017218953A1 (en) * 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
CA3058241A1 (en) * 2017-05-18 2018-11-22 Jiangsu Hengrui Medicine Co., Ltd. Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
EP3654956A4 (en) 2017-07-19 2021-04-28 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSION DEFECTS
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
CN109718377B (zh) * 2017-10-31 2021-03-26 中国科学院脑科学与智能技术卓越创新中心 KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用
US12396996B2 (en) 2019-08-06 2025-08-26 The General Hospital Corporation Compounds, pharmaceutical compositions, and methods of their use in reversing cancer chemoresistance
CN112870366B (zh) * 2019-11-29 2023-01-24 江苏恒瑞医药股份有限公司 Ezh2抑制剂在制备治疗肿瘤药物中的新用途
US12138320B2 (en) * 2020-05-11 2024-11-12 The University Of Chicago Composition and methods for tumor imaging and treatment
WO2024106879A1 (ko) * 2022-11-17 2024-05-23 인제대학교 산학협력단 Ezh2 저해제 및 btk 억제제를 포함하는, 암의 예방 또는 치료용 약제학적 조성물
EP4471958A4 (en) 2022-12-01 2025-05-07 LG Energy Solution, Ltd. BATTERY PACK
CN119662835B (zh) * 2025-02-20 2025-05-27 宁波熙宁检测技术有限公司 一种用于检测ezh2基因突变的核酸组合物、试剂盒及检测方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2760452A4 (en) 2011-09-30 2015-04-01 Glaxosmithkline Llc METHODS OF TREATING CANCER
TR201904660T4 (tr) 2012-03-12 2019-05-21 Epizyme Inc İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri.
DK3184523T3 (da) 2012-04-13 2019-08-19 Epizyme Inc N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.
IL308807B2 (en) * 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
WO2013173441A2 (en) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CN110898067A (zh) 2012-10-15 2020-03-24 Epizyme股份有限公司 癌症治疗方法
PE20150886A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US20140120083A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
AU2013361079B2 (en) 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZOL COMPOUNDS
RU2019134551A (ru) 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
SG11201602269QA (en) 2013-10-16 2016-04-28 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
PL3157527T3 (pl) 2014-06-17 2023-08-07 Epizyme, Inc. Inhibitory ezh2 do leczenia chłoniaka
BR112017010166A2 (en) 2014-11-17 2018-02-14 Epizyme, Inc. solid tumor treatment method, activity inhibition method, oral dosage form for treating a solid tumor, solid pharmaceutical formulation, process for preparing a pharmaceutical formulation, and solid pharmaceutical composition
CN108135908A (zh) 2015-04-20 2018-06-08 Epizyme股份有限公司 用于治疗癌症的组合疗法
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤

Also Published As

Publication number Publication date
US20180280402A1 (en) 2018-10-04
JP7323592B2 (ja) 2023-08-08
JP2020045350A (ja) 2020-03-26
US20220226336A1 (en) 2022-07-21
AU2014360078A1 (en) 2016-06-09
EP3076977A4 (en) 2017-08-16
JP2016539134A (ja) 2016-12-15
EP3076977A1 (en) 2016-10-12
IL245731B (en) 2021-05-31
MX373187B (es) 2020-04-13
EP3888659A1 (en) 2021-10-06
CN105873592A (zh) 2016-08-17
KR20160085365A (ko) 2016-07-15
CN116019921A (zh) 2023-04-28
IL282741A (en) 2021-06-30
AU2020202088B2 (en) 2022-04-28
US20160303135A1 (en) 2016-10-20
CN105873592B (zh) 2023-01-31
BR112016012713A2 (pt) 2017-08-08
KR102473113B1 (ko) 2022-12-01
MX2016007351A (es) 2017-02-13
ES2863996T3 (es) 2021-10-13
JP2022017495A (ja) 2022-01-25
KR20220165809A (ko) 2022-12-15
AU2020202088A1 (en) 2020-04-09
IL245731A0 (en) 2016-07-31
JP2023139230A (ja) 2023-10-03
IL282741B2 (en) 2024-01-01
US20200113911A1 (en) 2020-04-16
CA2931263A1 (en) 2015-06-11
KR20210117347A (ko) 2021-09-28
EP3076977B1 (en) 2021-03-03
IL304851A (en) 2023-09-01
IL282741B1 (en) 2023-09-01
WO2015085325A1 (en) 2015-06-11
US10463671B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
CY1124311T1 (el) Παρεμποδιστες dna-pk
EA201792304A1 (ru) Комбинированная терапия для лечения рака
NZ700759A (en) Combination therapy for treating cancer
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
MX2015016277A (es) Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa.
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
EA201590987A1 (ru) Соединения и способы их применения
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201600288A1 (ru) Замещенные фенилаланиновые производные
EA202091908A2 (ru) Комбинированная терапия для лечения онкологического заболевания
EA201592012A8 (ru) Применение флагеллина для улучшенной химиотерапии